Prior AICAR induces elevated glucose uptake concomitant with greater γ3-AMPK activation and reduced membrane cholesterol in skeletal muscle from 26-month-old rats

In contrast, only a modest and statistical nonsignificant increase in AMPK activity after AICAR injection could be detected in adipose tissue, and, correspondingly, the level of ZMP in this tissue was nearly undetectable. Still, the present study demonstrates an activation of AMPK in liver as well as in skeletal muscle as a consequence of in vivo AICAR administration, suggesting that this enzyme system is potentially involved in the mechanism of our findings. Although it is most likely that the chemical compound AICAR exerts its effects through activation of the AMPK, it cannot be ruled out that other cellular pathways are influenced by AICAR administration. For instance, a direct inhibitory effect on fructose-1,6-bisphosphatase and thereby suppression of hepatic gluconeogenesis by ZMP (AICAR monophosphate) has previously been proposed (30,42).

AICAR has previously been reported to increase metabolism and weight loss [7], even in sedentary mice [8]. Thus, it is not surprising that AICAR-treated HFD-fed mice gained less weight during the last weeks of the diet regimen, compared with vehicle-treated HFD-fed control mice. This effect on weight gain may have mediated some of the observed beneficial effects of AICAR, but it is unlikely that this is the sole protective mechanism of this compound since AICAR-treated HFD-fed mice weighed significantly more than controls fed an SFD.

• Western blot analysis of total α1 subunit protein revealed that adenoviral transduction with the mutant indeed resulted in a much higher protein abundance than its corresponding null vector used as a control.
• Collectively, this supports previous work from our group and others, demonstrating that AICAR attenuates both HFD-induced [12, 13] and diabetes-induced [14, 15] kidney disease.
• Since white adipose tissue (WAT) inflammation is a key driver of obesity-related pathophysiology [25,26,27,28,29], this was characterised in detail.
• 5-Aminoimidazole-4-carboxamide 1-β-d-ribofuranoside (AICAR, or acadesine) is a precursor of the monophosphate derivative 5-amino-4-imidazole carboxamide ribonucleoside 5′-phosphate (ZMP), an intermediate in de novo purine biosynthesis.

Both Schug’s and our ChIP assays indicate that macrophage SIRT1 deficiency increases p65 DNA binding to its consensus promoters [20], which may not be attributed to lysine 310 hyper-acetylation. Moreover, we found that SIRT1 deletion promotes iKKα/β phosphorylation, an upstream signal of p65 nuclear translocation, and also stimulates the phosphorylation of JNK, an inflammatory signal that parallels the iKK/NF-κB pathway. All these data suggest that SIRT1 deficiency alters the global inflammatory networks.

Cell Culture

The animal studies were approved by the institutional animal care and use committee of the Baptist Medical Center at Wake Forest University. DIO mice were randomly assigned to receive either saline or AICAR (Toronto Research Chemicals, North York, Ontario) injection http://r-shop.eu/discover-the-best-way-to-buy-trenbolone-acetate-a/ intraperitoneally (i.p.) daily for five weeks. At the AICAR dose of 150 mg/kg/day, we did not observe any body weight changes in established DIO mice. The increased p21 has been linked to AICAR-induced programmed cell death in thyroid cancer cells.

Introduction of these mutations into mice carrying RAS oncogenes led to strong resistance to tumour growth, initiation and maintenance. Furthermore, blocking the p110α/RAS interaction in wild type mice was found to be well tolerated, which highlights the significance of the p110α/RAS interaction as a cancer drug target20,21,22. Therefore, we were interested in finding inhibitors that block the interaction of p110α with RAS for future pharmaceutical studies. Consistent with the findings in the organotypic cultures, the activation of the hypothalamic AMPK signaling by replacement of glucocoticoids in ADX rats lead to increases in Npy and Agrp expression in the arcuate nucleus in the present study. On the other hand, ADX per se did not affect significantly the levels of Npy and Agrp mRNA expression in the arcuate nucleus, as reported in previous studies (9).

Immunoprecipitation and AMPK assays

It is also reported to down-regulate the synthesis of fatty acids as well as cholesterol [52]. These observations indicate participation of AMPK in the regulation of cellular energy metabolism. We have earlier reported on the anti-inflammatory role of AICAR via activation of AMPK in quenching LPS-induced pro-inflammatory responses by blockade of MAP kinase and IKK α/β-signaling cascades [19]. AICAR treatment activated AMP kinase activity, and antisense oligonucleotides for AMPKKα as well as expression of dominant negative cDNA of AMPKα in glia reversed the AICAR-mediated inhibition of iNOS gene expression in response to LPS treatment [19]. These above studies demonstrate AICAR attenuation of LPS- or cytokine/Aβ-induced expression of inflammatory mediators (e.g. iNOS, COX-2 and cytokines) by inhibiting the activation of transcription factors (NFκB and C/EBP) required for induction of the inflammatory process.

Increased dicarboxylic acid (DCA) levels are generally considered to indicate dysregulated mitochondrial and peroxisomal β-oxidation. Decreased plasma DCA in mice treated with MOTS-c indicates a higher efficiency of normal β-oxidation [72]. In a recent study, MOTS-c treatment significantly alleviated hyperglycemia and improved insulin sensitivity in gestational diabetic mice, and reduced mortality in offspring [76]. In conclusion, there may be more ways for MOTS-c to regulate metabolic homeostasis and insulin resistance, and this is a promising area for future research. Even though previous studies support AICAR’s treatment in leukaemia, hepatocarcinoma, and prostate cancer, our cell-based screening of cytotoxicity of AICAR was limited to its relatively smaller scale in lung cancer. Our data calls for high-throughput screening of various cancer cell lines in combination treatment with AICAR, JAK, or EGFR inhibitors.

• It will be interesting to explore if AICAR-induced MUC1-CT instability is correlated to MUC1-CT ubiquitination in the future.
• These results indicated that AMPK activation ameliorated the SREBP-2 up-regulation induced by TSH.
• Immortalised tracheobronchial epithelial (AALE) cells were derived as previously described and maintained in SAGM media (Lonza) [60].
• Furthermore, blocking the p110α/RAS interaction in wild type mice was found to be well tolerated, which highlights the significance of the p110α/RAS interaction as a cancer drug target20,21,22.
• Accumulation of amyloid-β protein, a pathological hallmark of AD, also contributes to many alterations of neuronal structure leading to axonal loss and consequent to neuronal cell loss [41, 42].
• Both human and murine lymphocytes (CD3+CD45+) were characterised as T helper (% CD4+ of CD3+CD45+) and cytotoxic T cells (% CD8+ of CD3+CD45+).

AICAR may improve insulin sensitivity and lipid metabolism via its possible anti-inflammatory role in different metabolic pathways. In diabetic murine models, AICAR was observed to reduce blood glucose levels without registering weight changes[6]. AICAR appears to mimic the action that physical activity may induce in glucose uptake by muscles. Researchers suggest that it has the potential to upregulate the GLUT-4 receptors on muscles that are prime transporters involved in glucose uptake. Our previous studies demonstrated that TSH up-regulates hepatic HMGCR and SREBP-2 expression (unpublished) in the liver [1].

Discover content

As shown in Fig 3A, the SREBP-2 precursor and nuclear active forms were decreased in the livers of Tshr-/- mice compared with Tshr+/+ mice, although the exact mechanisms by which this occurs remain unclear. The mRNA expression of HMGCR was also significantly reduced, and HMGCS mRNA expression exhibited a decreasing trend (Fig 3B). The expression vector pcDNA3.1–2×FLAG SREBP-2 (human, amino acids 1–481) was obtained from Addgene (Plasmid 26807,provided by Timothy Osbome, La Jolla, CA) [26].

Total abundance of signaling proteins

Quantitative proteomic analyses revealed 57 proteins significantly less abundant on nuclei-enriched fractions from AICAR-fed cells, this effect being compensated by overexpression of KAP123 for 15 of them. AICAR blocked LPS/Aβ-induced inflammatory processes by blocking the expression of proinflammatory cytokine, iNOS, COX-2 and MnSOD genes, and by inhibition of ROS generation and depletion of glutathione in astroglial cells. AICAR also inhibited down-stream signaling leading to the regulation of transcriptional factors such as NFκB and C/EBP which are critical for the expression of iNOS, COX-2, MnSOD and cytokines (TNF-α/IL-1β and IL-6). AICAR promoted NGF-induced neurite growth and reduced neurite outgrowth inhibition in PC-12 cells treated with astroglial conditioned medium. For immunoblotting, protein lysate (50–100 µg) was resolved by SDS-PAGE, and the phosphorylation and total levels of specific proteins were measured by immunoblotting.

Statistical analysis

However, higher concentrations of AICAR (2 mM) were found to be toxic (data not shown). In a similar set of experiments we observed similar protection of neurite extension by AICAR against cytokines (TNF-α and IL-1β)/Aβ (7.5 μM) (data not shown here). AICAR, short for 5-aminoimidazole-4-carboxamide ribonucleoside, is short peptide that plays a role in energy homeostasis and a number of metabolic pathways. AICAR plays a role in the regulation of insulin receptors and how muscle cells function with regards to insulin.

Effects of ADX and ip injection DEX on AMPK signaling in the arcuate nucleus

We tested whether the cyclo-CRVLIR peptide, as well as the other cyclo-CRVLAA 2nd derivatives (cyclo—CRVLID, CRVLRD, CRVLRR, CRVLKR, CRVLTR, CRVLKD), would be able to inhibit the p110α/KRAS interaction in cancer cell lines. We treated the human lung cancer cell line H1792, growing at steady-state in Roswell Park Memorial Institute (RPMI) 1640 media with 10% Foetal Calf Serum (FCS), with the seven cyclic peptides at three different concentrations (2, 10 and 50 µM) for 4 h. After treatment we measured the effect of the peptides on the phosphorylation levels of AKT (pAKT-Ser473), a key downstream effector of p110α activity. We found that cyclo-CRVLIR had a dose dependent effect on the levels of p-AKT, whereas the rest of the peptides showed almost no effect on p-AKT (Supplementary Fig. 5A,B).